If you made any changes in Pure these will be visible here soon.

Personal profile


  • 1994 中山醫學院醫學系學士


  • 2018- 臺北醫學大學癌症生物學與藥物研發研究所助理教授
  • 2016- 臺北醫學大學癌症生物學與藥物研發博士學位學程助理教授
  • 2007 臺北榮民總醫院義務特約醫師主治醫師
  • 2006-2007 國防醫學院三軍總醫院癌症病房主治醫師
  • 2000-2001 國立臺灣大學醫學院附設醫院血液腫瘤科住院醫師
  • 1995-2006 國家衛生研究院癌症研究所主治醫師
  • 1994-1995 臺北市立仁愛醫院麻醉科住院醫師

Fingerprint Dive into the research topics where Her-Shyong Shiah is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.



Shiah, H.


Project: B - Project of TMUg - Research Grants for Newly Hired Faculty

Research Output

  • 724 Citations
  • 15 h-Index
  • 27 Article
  • 1 Letter

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

de Bono, J., Lin, C. C., Chen, L. T., Corral, J., Michalarea, V., Rihawi, K., Ong, M., Lee, J. H., Hsu, C. H., Yang, J. C. H., Shiah, H. S., Yen, C. J., Anthoney, A., Jove, M., Buschke, S., Fuertig, R., Schmid, U., Goeldner, R. G., Strelkowa, N., Huang, D. C. L. & 3 others, Bogenrieder, T., Twelves, C. & Cheng, A. L., Apr 28 2020, In : British Journal of Cancer. 122, 9, p. 1324-1332 9 p.

Research output: Contribution to journalArticle

Open Access
  • Effective Sirolimus Treatment for Refractory Spindle Cell Haemangioma

    Ho, C. B., Hsieh, K., Chen, W. Y., Lin, Y. T., Chiou, J. F., Lee, H. L. & Shiah, H. S., May 11 2018, In : British Journal of Dermatology.

    Research output: Contribution to journalArticle

  • 5 Citations (Scopus)

    Effects of Dang-Gui-Bu-Xue-Tang, an herbal decoction, on iron uptake in iron-deficient anemia

    Huang, G. C., Chen, S. Y., Tsai, P. W., Ganzon, J. G., Lee, C. J., Shiah, H. S. & Wang, C. C., Mar 2 2016, In : Drug Design, Development and Therapy. 10, p. 949-957 9 p.

    Research output: Contribution to journalArticle

  • 7 Citations (Scopus)

    A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer

    Chen, J. S., Hsu, C., Chiang, N. J., Tsai, C. S., Tsou, H. H., Huang, S. F., Bai, L. Y., Chang, I. C., Shiah, H. S., Ho, C. L., Yen, C. J., Lee, K. D., Chiu, C. F., Rau, K. M., Yu, M. S., Yang, Y., Hsieh, R. K., Chang, J. Y., Shan, Y. S., Chao, Y. & 13 others, Chen, L. T., Chin, Y. H., Chung, T. R., Yu, W. L., Lee, M. H., Lin, L. F., Lin, P. C., Wu, Y. L., Wang, H. L., Lu, L. J., Chen, S. Y., Wu, C. C. & Wei, T. C., May 1 2015, In : Annals of Oncology. 26, 5, p. 943-949 7 p., mdv035.

    Research output: Contribution to journalArticle

  • 74 Citations (Scopus)